Details of the Drug

General Information of Drug (ID: DMN9CWF)

Drug Name

Salbutamol

Synonyms

Aerolin; Airomir; Almotex; Anebron; Asmadil; Asmanil; Asmasal; Asmatol; Asmaven; Asmidon; Asmol; Asthalin; Asthavent; Broncovaleas; Bronter; Bugonol; Bumol; Butamol; Butohaler; Butotal; Butovent; Buventol; Cetsim; Cobutolin; Dilatamol; Ecovent; Farcolin; Gerivent; Grafalin; Libretin; Medolin; Mozal; Novosalmol; Parasma; Pneumolat; Proventil; Respax; Respolin; Rotahaler; Sabutal; Sabutamol; Salamol; Salbetol; Salbron; Salbuhexal; Salbulin; Salbupur; Salbusian; Salbutalan; Salbutamolum; Salbutan; Salbutard; Salbutine; Salbutol; Salbuven; Salbuvent; Sallbupp; Salmaplon; Salomol; Salvent; Saventol; Servitamol; Solbutamol; Spreor; Sultanol; Suprasma; Suxar; Theosal; Tobybron; Vencronyl; Ventamol; Ventilan; Ventiloboi; Ventodisks; Ventoline; Volma; Volmax; Zaperin; Albuterol Sulphate; Albuterol [USAN]; Albuterol hemisulfate; Proventil HFA; Proventil Inhaler; Salbutamol Sulphate; Salbutamol sulfate; Sultanol N; Ventalin inhaler; Ventolin Inhaler; Ventolin Rotacaps; Volare albuterol HFA; AH 3365; S 8260; Aerolin (TN); Albuterol (USP); Alti-Salbutamol; Arubendol-Salbutamol; Asmol Uni-Dose; Asthalin (TN); Broncho-Spray; Buto-Asma; Dl-Albuterol; Dl-Salbutamol; ProAi (TN); Proventil (TN); Racemic-Salbutamol; Salbu-BASF; Salbu-Fatol; Salbutamolum [INN-Latin]; Ventolin (TN); Volare easi-breathe; R,S-Albuterol; Alpha-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha-diol; Alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol; DL-N-tert-Butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine; Alpha'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; Alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; (alpha1-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha-diol); 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol; 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol; 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol; 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; 4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol

Indication

Disease Entry	ICD 11	Status	REF
Acute asthma	CA23	Approved	[1], [2]

Therapeutic Class

Bronchodilator Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

239.31

Topological Polar Surface Area (xlogp)

0.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.42 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Clearance: The renal clearance of drug is 272 +/- 38 mL/min [5]
Elimination: After oral administration, 58-78% of the dose is excreted in the urine in 24 hours, approximately 60% as metabolites [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.7 - 5 hours [7]
Metabolism: The drug is not metabolised [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.22717 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.92% [7]
Vd: The volume of distribution (Vd) of drug is 156 +/- 38 L [5]

Chemical Identifiers

Formula: C13H21NO3
IUPAC Name: 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
Canonical SMILES: CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
InChI: InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3
InChIKey: NDAUXUAQIAJITI-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2083
ChEBI ID: CHEBI:2549
CAS Number: 18559-94-9
DrugBank ID: DB01001
TTD ID: D0K5CB
VARIDT ID: DR01406
INTEDE ID: DR1457
ACDINA ID: D00613

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-2 (ADRB2)	TT2CJVK	ADRB2_HUMAN	Agonist	[9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Carboxylesterase 1 (CES1)	DEB30C5	EST1_HUMAN	Substrate	[12]
Sulfotransferase 1A3 (SULT1A3)	DEP7E8X	ST1A3_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Acute asthma

ICD Disease Classification

CA23

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor beta-2 (ADRB2)	DTT	ADRB2	4.88E-01	-0.05	-0.12
Adrenergic receptor beta-2 (ADRB2)	DTT	ADRB2	7.10E-01	0.06	0.09
Organic cation transporter 1 (SLC22A1)	DTP	SLC22A1	1.48E-01	6.33E-02	3.20E-01
Organic cation transporter 1 (SLC22A1)	DTP	SLC22A1	1.74E-02	1.21E-01	4.40E-01
Carboxylesterase 1 (CES1)	DME	CES1	6.44E-02	-5.34E-02	-1.56E-01
Carboxylesterase 1 (CES1)	DME	CES1	3.03E-02	1.57E-01	2.30E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.13E-01	4.03E-02	2.50E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	8.21E-02	8.17E-02	4.35E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Salbutamol

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Budesonide	DMJIBAW	Minor	Increased risk of hypokalemia by the combination of Salbutamol and Budesonide.	Asthma [CA23]	[54]
-----------

Coadministration of a Drug Treating the Disease Different from Salbutamol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Moderate	Additive hypertensive effects by the combination of Salbutamol and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[55]
Ivosidenib	DM8S6T7	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Ivosidenib.	Acute myeloid leukaemia [2A60]	[56]
Midostaurin	DMI6E0R	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Midostaurin.	Acute myeloid leukaemia [2A60]	[57]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Idarubicin.	Acute myeloid leukaemia [2A60]	[57]
Arn-509	DMT81LZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Arn-509.	Acute myeloid leukaemia [2A60]	[57]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Gilteritinib.	Acute myeloid leukaemia [2A60]	[57]
Ivabradine	DM0L594	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Ivabradine.	Angina pectoris [BA40]	[57]
Bepridil	DM0RKS4	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Bepridil.	Angina pectoris [BA40]	[56]
Dronedarone	DMA8FS5	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Dronedarone.	Angina pectoris [BA40]	[56]
Bedaquiline	DM3906J	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[56]
Cilostazol	DMZMSCT	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Cilostazol.	Arterial occlusive disease [BD40]	[57]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Posaconazole.	Aspergillosis [1F20]	[57]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[57]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Salbutamol and Droxidopa.	Autonomic nervous system disorder [8D87]	[58]
Ofloxacin	DM0VQN3	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[57]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Salbutamol and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[59]
Sparfloxacin	DMB4HCT	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[56]
Gemifloxacin	DMHT34O	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[57]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[57]
Levofloxacin	DMS60RB	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[57]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Retigabine.	Behcet disease [4A62]	[57]
Lapatinib	DM3BH1Y	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Lapatinib.	Breast cancer [2C60-2C6Y]	[57]
Bosutinib	DMTI8YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Bosutinib.	Breast cancer [2C60-2C6Y]	[57]
Corticotropin	DMP9TWZ	Minor	Increased risk of hypokalemia by the combination of Salbutamol and Corticotropin.	Chronic kidney disease [GB61]	[54]
PF-04449913	DMSB068	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[57]
Levomilnacipran	DMV26S8	Moderate	Increased risk of rapid heart rate by the combination of Salbutamol and Levomilnacipran.	Chronic pain [MG30]	[60]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Halothane.	Corneal disease [9A76-9A78]	[57]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Sevoflurane.	Corneal disease [9A76-9A78]	[57]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Probucol.	Coronary atherosclerosis [BA80]	[57]
Pasireotide	DMHM7JS	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Pasireotide.	Cushing syndrome [5A70]	[56]
Osilodrostat	DMIJC9X	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Osilodrostat.	Cushing syndrome [5A70]	[57]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Sertraline.	Depression [6A70-6A7Z]	[57]
Selegiline	DM6034S	Moderate	Additive hypertensive effects by the combination of Salbutamol and Selegiline.	Depression [6A70-6A7Z]	[55]
Isocarboxazid	DMAF1NB	Moderate	Additive hypertensive effects by the combination of Salbutamol and Isocarboxazid.	Depression [6A70-6A7Z]	[55]
Milnacipran	DMBFE74	Moderate	Increased risk of rapid heart rate by the combination of Salbutamol and Milnacipran.	Depression [6A70-6A7Z]	[60]
Escitalopram	DMFK9HG	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Escitalopram.	Depression [6A70-6A7Z]	[56]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of rapid heart rate by the combination of Salbutamol and Desvenlafaxine.	Depression [6A70-6A7Z]	[60]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[57]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Deutetrabenazine.	Dystonic disorder [8A02]	[57]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Ingrezza.	Dystonic disorder [8A02]	[57]
Solifenacin	DMG592Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Solifenacin.	Functional bladder disorder [GC50]	[57]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Ketoconazole.	Fungal infection [1F29-1F2F]	[57]
Procarbazine	DMIK367	Moderate	Additive hypertensive effects by the combination of Salbutamol and Procarbazine.	Hodgkin lymphoma [2B30]	[55]
Saquinavir	DMG814N	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[61]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Phenolphthalein.	Irritable bowel syndrome [DD91]	[54]
Ceritinib	DMB920Z	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Ceritinib.	Lung cancer [2C25]	[56]
Osimertinib	DMRJLAT	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Osimertinib.	Lung cancer [2C25]	[56]
Selpercatinib	DMZR15V	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Selpercatinib.	Lung cancer [2C25]	[56]
Lumefantrine	DM29GAD	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Lumefantrine.	Malaria [1F40-1F45]	[56]
Halofantrine	DMOMK1V	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Halofantrine.	Malaria [1F40-1F45]	[56]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Hydroxychloroquine.	Malaria [1F40-1F45]	[57]
Primaquine	DMWQ16I	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Primaquine.	Malaria [1F40-1F45]	[57]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[57]
Arsenic trioxide	DM61TA4	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[56]
Vemurafenib	DM62UG5	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Vemurafenib.	Melanoma [2C30]	[56]
Panobinostat	DM58WKG	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Panobinostat.	Multiple myeloma [2A83]	[56]
Siponimod	DM2R86O	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Siponimod.	Multiple sclerosis [8A40]	[57]
Fingolimod	DM5JVAN	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Fingolimod.	Multiple sclerosis [8A40]	[57]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Ozanimod.	Multiple sclerosis [8A40]	[62]
Romidepsin	DMT5GNL	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Romidepsin.	Mycosis fungoides [2B01]	[57]
Dasatinib	DMJV2EK	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Dasatinib.	Myeloproliferative neoplasm [2A20]	[57]
Promethazine	DM6I5GR	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Promethazine.	Nausea/vomiting [MD90]	[57]
Entrectinib	DMMPTLH	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Entrectinib.	Non-small cell lung cancer [2C25]	[57]
Sibutramine	DMFJTDI	Moderate	Increased risk of rapid heart rate by the combination of Salbutamol and Sibutramine.	Obesity [5B80-5B81]	[63]
Levomethadyl Acetate	DM06HG5	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Levomethadyl Acetate.	Opioid use disorder [6C43]	[56]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Lofexidine.	Opioid use disorder [6C43]	[57]
Rucaparib	DM9PVX8	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Rucaparib.	Ovarian cancer [2C73]	[57]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Triclabendazole.	Parasitic worm infestation [1F90]	[57]
Safinamide	DM0YWJC	Moderate	Additive hypertensive effects by the combination of Salbutamol and Safinamide.	Parkinsonism [8A00]	[55]
Rasagiline	DM3WKQ4	Moderate	Additive hypertensive effects by the combination of Salbutamol and Rasagiline.	Parkinsonism [8A00]	[55]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Pimavanserin.	Parkinsonism [8A00]	[57]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Salbutamol and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[64]
Lefamulin	DME6G97	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Lefamulin.	Pneumonia [CA40]	[56]
Degarelix	DM3O8QY	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Degarelix.	Prostate cancer [2C82]	[57]
ABIRATERONE	DM8V75C	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and ABIRATERONE.	Prostate cancer [2C82]	[57]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Enzalutamide.	Prostate cancer [2C82]	[57]
Relugolix	DMK7IWL	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Relugolix.	Prostate cancer [2C82]	[57]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Bicalutamide.	Prostate cancer [2C82]	[57]
Levomepromazine	DMIKFEL	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Levomepromazine.	Psychotic disorder [6A20-6A25]	[57]
Gatifloxacin	DMSL679	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[56]
Ciclesonide	DM2NA4K	Minor	Increased risk of hypokalemia by the combination of Salbutamol and Ciclesonide.	Respiratory system disease [CB40-CB7Z]	[54]
Dexamethasone	DMMWZET	Minor	Increased risk of hypokalemia by the combination of Salbutamol and Dexamethasone.	Rheumatoid arthritis [FA20]	[54]
Quetiapine	DM1N62C	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Quetiapine.	Schizophrenia [6A20]	[57]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Aripiprazole.	Schizophrenia [6A20]	[54]
Iloperidone	DM6AUFY	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Iloperidone.	Schizophrenia [6A20]	[56]
Paliperidone	DM7NPJS	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Paliperidone.	Schizophrenia [6A20]	[57]
Amisulpride	DMSJVAM	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Amisulpride.	Schizophrenia [6A20]	[56]
Asenapine	DMSQZE2	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Asenapine.	Schizophrenia [6A20]	[57]
Pimozide	DMW83TP	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Pimozide.	Schizophrenia [6A20]	[56]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Salbutamol and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[59]
Vandetanib	DMRICNP	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[56]
Triptorelin	DMTK4LS	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[57]
Pitolisant	DM8RFNJ	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Pitolisant.	Somnolence [MG42]	[57]
Telavancin	DM58VQX	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[57]
Lenvatinib	DMB1IU4	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Lenvatinib.	Thyroid cancer [2D10]	[57]
Cabozantinib	DMIYDT4	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Cabozantinib.	Thyroid cancer [2D10]	[56]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Salbutamol and Papaverine.	Tonus and reflex abnormality [MB47]	[65]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[57]
Fluticasone	DMGCSVF	Minor	Increased risk of hypokalemia by the combination of Salbutamol and Fluticasone.	Vasomotor/allergic rhinitis [CA08]	[54]
Procainamide	DMNMXR8	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Procainamide.	Ventricular tachyarrhythmia [BC71]	[56]
Propafenone	DMPIBJK	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Propafenone.	Ventricular tachyarrhythmia [BC71]	[57]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Salbutamol and Flecainide.	Ventricular tachyarrhythmia [BC71]	[57]
Amiodarone	DMUTEX3	Moderate	Increased risk of ventricular arrhythmias by the combination of Salbutamol and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[56]
-----------


⏷ Show the Full List of 106 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium sulfate anhydrous	E00303	24497	Desiccant; Diluent
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Salbutamol 4 mg tablet	4 mg	12 HR Extended Release Oral Tablet	Oral
Salbutamol 8 mg tablet	8 mg	12 HR Extended Release Oral Tablet	Oral
Salbutamol 2 mg tablet	2 mg	Oral Tablet	Oral
Salbutamol 4 mg tablet	4 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 558).
2	Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	BDDCS applied to over 900 drugs
5	Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, Ziccone SP: Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol. 1986 Nov;22(5):587-93.
6	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
10	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
11	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
12	Effect of carboxylesterase 1 c.428G>A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol. 2015 Nov;80(5):1131-8.
13	SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? Drug Test Anal. 2015 Feb;7(2):109-13.
14	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23	Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23.
24	Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and portal vein cannulation models. Biopharm Drug Dispos. 2015 Sep;36(6):385-397.
25	Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1. Drug Metab Dispos. 2013 Nov;41(11):1888-95.
26	Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004 Aug;310(2):469-76.
27	Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010 Nov 5;285(45):34337-47.
28	Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.
29	Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder. Neuropsychiatr Dis Treat. 2006 Dec;2(4):467-73.
30	Summary of FDA-approved anticancer cytotoxic drugs at May 2019.
31	Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019 Jan 17;9(1). pii: E7.
32	Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704.
33	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
34	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
35	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
36	Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
37	Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
38	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
39	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
40	Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
41	Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
42	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
43	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
44	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
45	Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
46	Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
47	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
48	Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
49	Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
50	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
51	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
52	Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.
53	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353).
54	Cerner Multum, Inc. "Australian Product Information.".
55	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
56	Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
57	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
58	Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
59	Canadian Pharmacists Association.
60	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
61	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
62	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
63	Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
64	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
65	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]